LY-354740 (Eli Lilly).

No abstract is available for this paper.

• Publication year

  2003

• Venue

  IDrugs : the investigational drugs journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 12789623
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of striatal metabotropic glutamate receptors in Parkinson's disease

  2002cited by this paper
• (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.

  2002cited by this paper
• The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.

  2002cited by this paper
• Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats.

  2002cited by this paper
• Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice.

  2002cited by this paper
• The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs.

  2002cited by this paper
• The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration

  2001cited by this paper
• Interactions between LY354740, a Group II metabotropic agonist and the GABAA-benzodiazepine receptor complex in the rat elevated plus-maze

  2001cited by this paper
• Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

  2000cited by this paper
• LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.

  2000cited by this paper
• LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats.

  2000cited by this paper
• Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata

  2000cited by this paper
• Roles of group II metabotropic glutamate receptors in modulation of seizure activity

  2000cited by this paper
• Cocaine and kindling alter the sensitivity of group II and III metabotropic glutamate receptors in the central amygdala.

  2000cited by this paper
• The role of glutamate receptors in antipsychotic drug action

  2000cited by this paper
• Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice

  2000cited by this paper
• Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats

  2000cited by this paper
• Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors

  2000cited by this paper
• Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795.

  1999cited by this paper
• Neuroprotective Actions of Novel and Potent Ligands of Group I and Group II Metabotropic Glutamate Receptors

  1999cited by this paper
• Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity.

  1999cited by this paper
• The retention deficit induced by (RS)-α-methyl-4-carboxyphenylglycine in a lever-press learning task is blocked by selective agonists of either group I or group II metabotropic glutamate receptors

  1999cited by this paper
• Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures.

  1999cited by this paper
• Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models.

  1999cited by this paper
• Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury.

  1999cited by this paper
• The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.

  1999cited by this paper
• Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.

  1999cited by this paper
• Pharmacological agents acting at subtypes of metabotropic glutamate receptors.

  1999cited by this paper
• The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal.

  1999cited by this paper
• Neuroprotective effects of a systemically active Group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia

  1998cited by this paper
• LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats

  1998cited by this paper
• Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

  1998cited by this paper
• Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.

  1998cited by this paper
• 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.

  1998cited by this paper
• 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution.

  1998cited by this paper
• Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist

  1998cited by this paper
• In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats.

  1997cited by this paper
• A novel orally active Group 2 metabotropic glutamate receptor agonist: LY354740

  1997cited by this paper
• LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats.

  1997cited by this paper
• LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.

  1997cited by this paper
• Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus

  1997cited by this paper
• Pharmacology and functions of metabotropic glutamate receptors.

  1997cited by this paper
• Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.

  1997cited by this paper
• Pharmacological characterization of metabotropic glutamate receptors linked to the inhibition of adenylate cyclase activity in rat striatal slices.

  1997cited by this paper
• The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations.

  1996cited by this paper
• Excitatory amino acid receptors in the vertebrate central nervous system.

  1989cited by this paper

• LY354740 Reduces Extracellular Glutamate Concentration, Inhibits Phosphorylation of Fyn/NMDARs, and Expression of PLK2/pS129 α-Synuclein in Mice Treated With Acute or Sub-Acute MPTP

  2020cites this paper
• Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.

  2020cites this paper
• Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo.

  2012cites this paper
• Machine learning algorithms for prediction of biological activity and chemical properties

  2011cites this paper
• Investigation on Quantitative Structure Activity Relationships and Pharmacophore Modeling of a Series of mGluR2 Antagonists

  2011cites this paper
• Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening

  2010cites this paper
• Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition

  2009cites this paper
• Metabotropic Glutamate Receptor Ligands as Novel Therapeutic Agents

  2008cites this paper
• Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells.

  2008cites this paper
• Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.

  2007cites this paper
• Metabotropic glutamate receptors

  2007cites this paper
• Sites of action and physiological impact of mGluR5 positive allosteric modulators.

  2007cites this paper
• Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses

  2007cites this paper
• Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.

  2006cites this paper
• Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.

  2005cites this paper
• Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys

  2005cites this paper
• LY-544344. Eli Lilly.

  2005cites this paper
• Glutamate as a therapeutic target in psychiatric disorders

  2004cites this paper